Abstract
Gaps in knowledge exist regarding the clinical characteristics of psoriatic disease in ethnic minority patients. We evaluated validated clinical disease measures of psoriasis and psoriatic arthritis in African-American and Caucasian patients. Adult outpatients with confirmed diagnoses of psoriasis and psoriatic arthritis and seen at four urban academic institutions were eligible for evaluation. Validated patient and physician-reported disease outcome parameters, quality of life measures of psoriasis and psoriatic arthritis, and frequencies of systemic immunosuppressive therapies and patient comorbidities were documented. Psoriatic arthritis was less frequent in African-Americans compared to Caucasians (30 vs. 64.5 %, respectively, p < 0.001); however, African-Americans had more severe skin involvement [Psoriasis Area and Severity Index 8.4 (10.0) vs. Caucasians 5.5 (6.4), p = 0.06], with greater psychological impact and impaired quality of life. Use of biologic therapies was greater in Caucasian patients (46.2 vs. 13.3 % in African-Americans, p < 0.0001); yet, only one in four patients of the study cohort achieved minimal disease activity. Comorbidity was not associated with frequency of immunosuppressive drug use. In order to achieve a target of low disease activity and to reduce ethnic disparities in the care of psoriatic disease, the routine application of measures of disease status is needed.
Similar content being viewed by others
References
Ibrahim G, Waxman R, Helliwell PS (2009) The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61(10):1373–1378
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases 64(Suppl 2):ii14–17
Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ (2005) Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 141(12):1537–1541
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM (2009) Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 61(2):233–239
Lee S, Mendelsohn A, Sarnes E (2010) The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T 35(12):680–689
Papoutsaki M, Costanzo A (2013) Treatment of psoriasis and psoriatic arthritis. BioDrugs 27(Suppl 1):3–12. doi:10.1007/BF03325637
Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ (2005) The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 52(1):23–26
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53(4):573
Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70(3):512–6. doi:10.1016/j.jaad.2013.11.013
Gisondi P, Rossini M, Di Cesare A, Idolazzi L, Farina S, Beltrami G, Peris K, Girolomoni G (2012) Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol 166(3):505–510
Touma Z, Eder L, Zisman D, Feld J, Chandran V, Rosen CF, Shen H, Cook RJ, Gladman DD (2011) Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. Arthritis Care Res (Hoboken) 63(10):1440–1447
Bruce IN, Schentag CT, Gladman DD (2000) Hyperuricemia in psoriatic arthritis: prevalence and associated features. J Clin Rheumatol 6(1):6–9
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, Group CS (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673
Prevoo ML, Hof MA V’t, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48
Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48–53
Pincus T, Sokka T, Kautiainen H (2005) Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol 32(8):1432–1439
Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483
McKenna SP, Cook SA, Whalley D, Doward LC, Richards HL, Griffiths CE, Van Assche D (2003) Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 149(2):323–331
McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63(2):162–169
Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL (1993) Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 42(2):93–99
Silveira E, Taft C, Sundh V, Waern M, Palsson S, Steen B (2005) Performance of the SF-36 health survey in screening for depressive and anxiety disorders in an elderly female Swedish population. Qual Life Res 14(5):1263–1274
Child FJ, Fuller LC, Higgins EM, Du Vivier AW (1999) A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol 141(3):512–517
Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA (1983) Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis 32(4):388–390
Kenney JA (1965) Management of dermatoses peculiar to Negroes. Arch Dermatol 91:126–129
Eder L, Chandran V, Shen H, Cook RJ, Shanmugarajah S, Rosen CF, Gladman DD (2011) Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) 63(4):619–622
Coates LC, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Burden-The E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H et al (2013) Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 168(4):802–807
Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (2013) Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol Inflamm 40(3):287–293
Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, Mehta NN, Troxel A, Choi H, Gelfand JM (2013) Prevalence and treatment patterns of psoriatic arthritis in the UK. J Rheumatol 52(3):568–575
Kim IH, West CE, Kwatra SG, Feldman SR, O’Neill JL (2012) Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 13(6):365–374
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL et al (2011) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 65(1):137–174
Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68(9):1387–1394
Gladman DD, Chandran V, Thavaneswaran A, Zummer M (2012) Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology. J Rheumatol 39(9):1850–1853
Wong PC, Leung YY, Li EK, Tam LS (2012) Measuring disease activity in psoriatic arthritis. Int J Rheumatol 2012:839425
Coates LC, Navarro-Coy N, Brown SR, Brown S, McParland L, Collier H, Skinner E, Law J, Moverley A, Pavitt S et al (2013) The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord 14:101
Dewalt DA, Berkman ND, Sheridan S, Lohr KN, Pignone MP (2004) Literacy and health outcomes: a systematic review of the literature. J Gen Intern Med 19(12):1228–1239
van Ryn M (2002) Research on the provider contribution to race/ethnicity disparities in medical care. Med Care 40(1 Suppl):I140–151
Putrik P, Sokka T, Ramiro S, Boonen A (2012) Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): lessons from QUEST RA. Best Pract Res Clin Rheumatol 26(5):705–720
McBurney CA, Vina ER (2012) Racial and ethnic disparities in rheumatoid arthritis. Curr Rheumatol Rep 14(5):463–471
Kerr G, Mikuls T, Yazici Y, Swearingen CJ, Luo C (2013) Disparity in biologic therapy in ethnic minorities with rheumatoid arthritis: can it all be due to lack of equal access to drug? Arthritis Rheum. 65 (10),#1713.
McMichael AJ, Vachiramon V, Guzmán-Sánchez DA, Camacho F (2012) Psoriasis in African-Americans: a caregivers’ survey. J Drugs Dermatol 11(4):478–482
Kim JH, Kim BY, Choi JW, Kim SO, Lee HS, Park KC, Youn SW (2012) The objective evaluation of the severity of psoriatic scales with desquamation collecting tapes and image analysis. Skin Res Technol 18(2):143–150
Murphy LB, Sacks JJ, Brady TJ, Hootman JM, Chapman DP (2012) Anxiety and depression among US adults with arthritis: prevalence and correlates. Arthritis Care Res (Hoboken) 64(7):968–976
Persson LO, Berglund K, Sahlberg D (1999) Psychological factors in chronic rheumatic diseases—a review. The case of rheumatoid arthritis, current research and some problems. Scand J Rheumatol 28(3):137–144
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM (2010) The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 146(8):891–895
Husted JA, Thavaneswaran A, Chandran V, Gladman DD (2013) Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol 40(8):1349–1356
Ryan C, Korman N, Gelfand J, Lim H, Elmets CA, Feldman S, Gottlieb A, Koo J, Lebwohl M, Leonardi C, Van Voorhees A, Bhushan R, Menter A (2014) Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. doi:10.1016/j.jaad.2013.08.042
Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R et al (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72(6):986–991
Acknowledgments
The study was supported by an investigator-initiated grant from AbbVie and Amgen pharmaceutical companies. The funding sources had no role in design, analysis, or manuscript preparation. The authors thank Kepher Makambi, PhD, and Yaru Shi, MS, for their assistance with statistical analyses.
Conflict of interest
Gail Kerr has served on a Pfizer Advisory Panel for Psoriatic Arthritis. Seema Quayumi, John Richards, Hashem Vahabzadeh-Monshie, Chesahna Kindred, Sean Whelton, and Florina Constantinescu declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kerr, G.S., Qaiyumi, S., Richards, J. et al. Psoriasis and psoriatic arthritis in African-American patients—the need to measure disease burden. Clin Rheumatol 34, 1753–1759 (2015). https://doi.org/10.1007/s10067-014-2763-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-014-2763-3